Paratek Pharmaceuticals entered a merger agreement on March 19, 2025, to acquire OptiNose, Inc. (OPTN) for $330 million.
Under the agreement, Paratek will acquire all outstanding shares of Optinose for $9 per share in cash, plus up to $5 per share in contingent value rights (CVRs) based on XHANCE’s net revenue milestones. Paratek will pay an additional $1 per share if XHANCE reaches $150 million in net sales in any calendar year before December 31, 2028, and $4 per share if it reaches $225 million in any calendar year before December 31, 2029.